Changes of Treg cells and Th1 and Th2 cytokines in peripheral blood
of patients with ovarian cancer and their relationship with
tumor pathological characteristics
UI Penghua1, LI UI Peng-hua1, LI Zhi-yan1, ZHANG Yu-juan1, LIU Li2
(1. Department of Gynaecology, 2.Clinical laboratory, the Affiliated Hospital of Chengde Medical College, Chengde Hebei 067000, China)
Abstract：Objective: To investigate the percentage of Treg cells in T cells in peripheral blood of ovarian cancer patients and the expression levels of Th1 cells and Th2 cytokines, and analyze the relationship between the above indicators and the clinicopathological characteristics of ovarian cancer. Methods: A total of 60 patients were chosen as malignant group with ovarian cancer who had been treated by laparoscopic ovarian cancer radical surgery and pathologically confirmed. In addition, 60 cases of benign ovarian diseases(benign group) and 60 cases of healthy women(control group) admitted by the hospital during the same period were enrolled. Changes of Treg cells and Th1 and Th2 cytokines in peripheral blood of each group were determined. The levels of Treg cells and Th1 and Th2 cytokines in different clinical stages and histological type were analyzed. Results: Between the control group and the benign group, there was no significant difference in the levels of cytokines IL2, IL4, IL10, INFγ, TNFα and the proportion of Treg cells in peripheral blood CD4+T cells(P>0.05). Compared with the control group and the benign group, the level of IL2 in the malignant group was significantly decreased(P<0.05), while the levels of IL2, INFγ and TNFα in the malignant group were lower than those in the control group and the benign group(P<0.05)， while the levels of IL4, IL10 and the percentage of Treg cells were higher than those in the control group and the benign group(P<0.05). With the increasing of clinical stage of ovarian cancer, the INFγ, TNFα levels gradually decreased (P<0.05), but the magnitude of IL2 changes did not reach statistical significance. The expression levels of IL4 and IL10 gradually increased, and the proportion of Treg cells also increased(P<0.05). Compared with mucinous property type and other histological type, IL4, IL10 and TNFα levels of serious ovarian cancer were significantly increased(P<0.05). Conclusion: The levels of both Th1 and Th2 cell cytokines in peripheral blood of patients with ovarian cancer at different clinical pathology and clinical stage is unbalanced. With the progression of clinical stage, the percentage of Treg cells in patients with malignant ovarian cancer is increased.
收稿日期: 2018-09-12
基金资助:河北省承德市科技计划项目(201706A037)
作者简介: 崔彭华(1982—)，女，河北承德人，硕士，主治医师，主要从事妇科肿瘤方面的研究。
引用本文:
崔彭华1, 李志艳1, 张玉娟1, 刘莉2. 卵巢癌患者外周血Treg细胞和Th1、Th2细胞因子的变化及其与临床病理特征的关系[J]. 江苏大学学报:医学版, 2019, 29(02): 153-156.
UI Peng-hua1, LI Zhi-yan1, ZHANG Yu-juan1, LIU Li2. Changes of Treg cells and Th1 and Th2 cytokines in peripheral blood
of patients with ovarian cancer and their relationship with
tumor pathological characteristics. Journal of Jiangsu University(Medicine Edition), 2019, 29(02): 153-156.
［1］Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of primary ovarian cancer by retargeting autologous cytokineinduced killer cells with bispecific antibodies: a preclinical study［J］. Clin Cancer Res, 2006,12(6): 1859-1867.［2］孙洁,杨素芬,白图门,等. 卵巢癌患者腹水及外周血CD4+CD25+调节性T细胞含量及抑制功能的研究［J］. 中国性科学,2016,25(2):17-19.［3］Gao Y, Foster R, Yang X, et al. Upregulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer［J］.Oncotarget, 2015, 6(11):9313-9326.［4］张秀丽,仝莹莹,张莲,等. 肿瘤免疫治疗新进展及面临挑战［J］. 癌症进展,2016, 14(2):129-133.［5］叶华,吴琼,郭蒙,等. 半枝莲多糖对C26荷瘤小鼠血清Th1／Th2亚群细胞因子的影响［J］. 癌症进展,2013,11(1):68-70,81.［6］曾英,李伟娟,章文娟,等. 壮骨止痛胶囊对去卵巢骨质疏松大鼠骨组织Treg／Th17平衡的调节作用［J］. 北京中医药大学学报,2016,39(7):555-561.［7］王丽华,王亮亮,张競,等. 卵巢癌患者外周血Th1／Th2及Treg／Th17细胞平衡关系［J］. 南方医科大学学报,2017,37(8):1066-1070.［8］莫婧,谭广萍,韦露薇,等.CD4+T细胞亚群Th1／Th2和Th17／Treg在卵巢癌中的分布及意义［J］.中国老年学杂志,2018,38(23):5703-5705.［9］崔彭华,李志艳,张玉娟,等.卵巢癌患者外周血免疫指标及炎性因子的检测及临床意义［J］.中国计划生育学杂志,2018,26(11):1098-1101.［10］王俞,崔书中. 恶性肿瘤患者的免疫功能状态及免疫治疗研究进展［J］. 中国肿瘤临床,2014,41(13):876-879.［11］王明雪,殷杰,张立刚,等. 艾迪注射液抗肿瘤作用及其对Th1／Th2免疫调节机制探讨［J］. 广州中医药大学学报,2017,34(2):299-302.［12］王婧瑶. 卵巢癌患者髓源性抑制细胞、调节性T细胞及其相关细胞因子的表达及临床意义［D］. 天津:天津医科大学,2015.［13］符婕,陈慧娟,栾莹,等. 血浆miR相关指标及Th1Th2类细胞因子与卵巢癌的关系研究［J］. 实用癌症杂志,2017,32(5):742-744.［14］彭蓉蓉,王胜军.肺癌患者外周血中髓源性抑制细胞的比例及其意义［J］.江苏大学学报(医学版),2019,29(1):54-57.［15］梁晶. 肺癌患者外周血Treg细胞与IL10、TGFβ检测及其临床意义［J］. 临床肺科杂志,2015,20(11):1980-1983.［16］谭玉洁,谢春霞,张惠,等.子宫颈癌患者Treg及Th细胞因子测定的临床意义［J］. 检验医学与临床,2016,13(9):1174-1176.［17］毛柳. 卵巢癌腹水及外周血CD4+CD25+Treg／CD4+T细胞含量及其意义分析［J］. 中国妇幼保健,2016,31(22):4871-4874.
2019, Vol. 29 
